Anticholinergic Drugs and Cholinesterase Inhibitors
Start with the big picture
Anticholinergics reduce parasympathetic activity by competitively blocking muscarinic receptors; they do not block nicotinic receptors. Atropine can enter the central nervous system, whereas quaternary agents such as ipratropium and glycopyrrolate remain peripheral. Their uses vary by drug, and adverse effects can include dry mouth, blurred vision, urinary retention, and delirium. Cholinesterase inhibitors increase acetylcholine at muscarinic and nicotinic sites. Examples include agents used for myasthenia gravis, reversal of certain neuromuscular blockers, and modest cognitive benefit in Alzheimer disease. Organophosphate exposure can cause a life-threatening cholinergic crisis. The full lesson develops these distinctions, toxicity patterns, contraindications, and antidote principles.
What you'll learn
- Explain how anticholinergics and cholinesterase inhibitors alter acetylcholine signaling.
- Distinguish central from peripheral anticholinergic effects using drug properties.
- Match representative drugs with the clinical uses described in the lesson.
- Recognize characteristic anticholinergic and cholinergic toxicity patterns.
- Summarize antidote principles for severe atropine toxicity and organophosphate poisoning.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
